Profile data is unavailable for this security.
About the company
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
- Revenue in USD (TTM)31.32m
- Net income in USD-126.78m
- Incorporated2013
- Employees172.00
- LocationVoyager Therapeutics Inc75 Hayden AvenueLEXINGTON 02421United StatesUSA
- Phone+1 (857) 259-5340
- Fax+1 (302) 655-5049
- Websitehttps://www.voyagertherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMP4 Therapeutics Corp | 3.80m | -53.40m | 204.15m | 55.00 | -- | 3.14 | -- | 53.70 | -2.48 | -2.48 | 0.1746 | 1.25 | 0.0706 | -- | 1.81 | 69,127.27 | -99.11 | -- | -121.32 | -- | -- | -- | -1,404.47 | -- | -- | -- | 0.0013 | -- | 86.29 | -- | -5.07 | -- | -- | -- |
| Quantum-Si Inc | 3.18m | -116.85m | 204.28m | 143.00 | -- | 0.8686 | -- | 64.30 | -0.6589 | -0.6589 | 0.0176 | 1.09 | 0.0128 | 0.404 | 3.58 | 22,216.78 | -47.06 | -- | -50.90 | -- | 51.65 | -- | -3,677.97 | -11,135.53 | 10.59 | -- | 0.00 | -- | 182.62 | -- | -5.26 | -- | -- | -- |
| Humacyte Inc | 1.57m | -36.97m | 206.51m | 218.00 | -- | -- | -- | 131.45 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 208.31m | 3.00 | -- | -- | -- | 3,472.48 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| Prenetics Global Ltd | 92.39m | -52.70m | 215.68m | 285.00 | -- | 0.9907 | -- | 2.33 | -3.60 | -4.02 | 6.58 | 15.43 | 0.443 | 6.38 | 22.48 | -- | -26.36 | -55.58 | -31.23 | -71.68 | 52.97 | 47.68 | -59.49 | -381.63 | 2.76 | -13.87 | 0.01 | -- | 479.76 | 7.23 | -51.06 | -- | 77.92 | -- |
| Heron Therapeutics Inc | 154.90m | -20.20m | 216.82m | 128.00 | -- | 16.30 | -- | 1.40 | -0.1205 | -0.1205 | 0.8733 | 0.0761 | 0.6335 | 0.5668 | 1.84 | 1,210,188.00 | -8.26 | -41.54 | -13.40 | -61.25 | 73.31 | 60.34 | -13.04 | -88.20 | 1.51 | -0.2662 | 0.9075 | -- | 7.36 | 11.81 | -48.71 | -- | -45.86 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 218.62m | 32.00 | -- | 56.53 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 218.67m | 12.00 | -- | 2.99 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 221.31m | 23.00 | -- | 2.71 | -- | 33.48 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 224.74m | 174.00 | -- | 0.9593 | -- | 2.30 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 226.29m | 172.00 | -- | 1.03 | -- | 7.23 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Surrozen Inc | 3.60m | -86.91m | 230.14m | 40.00 | -- | -- | -- | 63.86 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 230.50m | 25.00 | -- | 6.80 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 230.74m | 13.00 | -- | 12.15 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 230.92m | 15.00 | -- | 1.96 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Alector Inc | 21.05m | -142.93m | 232.87m | 103.00 | -- | 7.60 | -- | 11.07 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
Data as of Mar 04 2026. Currency figures normalised to Voyager Therapeutics Inc's reporting currency: US Dollar USD
43.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 31 Dec 2025 | 4.00m | 7.20% |
| Armistice Capital LLCas of 31 Dec 2025 | 4.00m | 7.19% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.92m | 7.05% |
| Millennium Management LLCas of 16 Jan 2026 | 3.41m | 6.13% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.95m | 5.30% |
| Vestal Point Capital LPas of 31 Dec 2025 | 1.48m | 2.65% |
| Opaleye Management, Inc.as of 31 Dec 2025 | 1.20m | 2.15% |
| Erste Asset Management GmbHas of 31 Dec 2025 | 1.20m | 2.15% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.14m | 2.04% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 1.05m | 1.90% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
